A Phase 2, Open-label Study of Ibrutinib Plus Rituximab in Japanese Patients with Waldenstrom's Macroglobulinemia

Overview

Journal Int J Hematol

Specialty Hematology

Date 2024 Apr 10

PMID 38597986

Authors

Koji Izutsu

Hisashi Kato

Naohiro Sekiguchi

Tomoaki Fujisaki

Toshiro Kawakita

Naoshi Obara

Kosei Matsue

Mitsutaka Nishimoto

Tomoyoshi Hatayama

Mitsuo Inagaki

Ei Fujikawa

Affiliations

Soon will be listed here.

Abstract

Ibrutinib is a first-in-class Bruton kinase inhibitor against B-cell neoplasms including Waldenström macroglobulinemia (WM). This study evaluated the efficacy and safety of ibrutinib-rituximab in Japanese patients with WM. Patients received ibrutinib 420 mg orally once daily plus weekly rituximab 375 mg/m IV (8 infusions total). The primary end point was major response rate (MRR; PR or better) by Independent Review Committee assessment. Secondary endpoints were progression-free survival (PFS), safety, pharmacokinetics, and biomarkers. Primary analysis was conducted in 16 patients [baseline, treatment naïve: 8 (50.0%); relapsed/refractory WM: 8 (50.0%)] who received ibrutinib-rituximab, after all patients completed Week 57 or end of treatment. At primary analysis, MRR was 87.5% [14/16 patients; 95% CI: 61.7, 98.4%; p < 0.0001 (null hypothesis: 32% response rate)]. At final analysis (median study intervention duration: 34.4 months, median follow-up: 35.0 months), MRR was unchanged at 87.5%, but VGPR [6/16 (37.5%)] and PR [8/16 (50.0%)] improved. Prior treatment status did not affect response. At final analysis, median PFS was not reached [36-month PFS rate: 86% (95% CI: 55, 96%)]. No critical safety signals were reported. This study demonstrated a positive benefit/risk profile of ibrutinib-rituximab in Japanese patients with WM, consistent with the iNNOVATE study.

References

Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H . A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. Cancer Sci. 2020; 111(9):3327-3337. PMC: 7469793. DOI: 10.1111/cas.14561. View

Treon S, Tripsas C, Meid K, Warren D, Varma G, Green R . Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015; 372(15):1430-40. DOI: 10.1056/NEJMoa1501548. View

OBrien S, Furman R, Coutre S, Flinn I, Burger J, Blum K . Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018; 131(17):1910-1919. PMC: 5921964. DOI: 10.1182/blood-2017-10-810044. View

Coutre S, Byrd J, Hillmen P, Barrientos J, Barr P, Devereux S . Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019; 3(12):1799-1807. PMC: 6595265. DOI: 10.1182/bloodadvances.2018028761. View

Kyle R, Treon S, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M . Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30(2):116-20. DOI: 10.1053/sonc.2003.50038. View

McMaster M . The epidemiology of Waldenström macroglobulinemia. Semin Hematol. 2023; 60(2):65-72. PMC: 10351685. DOI: 10.1053/j.seminhematol.2023.03.008. View

Pratt G, El-Sharkawi D, Kothari J, DSa S, Auer R, McCarthy H . Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022; 197(2):171-187. DOI: 10.1111/bjh.18036. View

Treon S, Meid K, Gustine J, Yang G, Xu L, Liu X . Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2020; 39(6):565-575. PMC: 8078354. DOI: 10.1200/JCO.20.00555. View

Marostica E, Sukbuntherng J, Loury D, De Jong J, de Trixhe X, Vermeulen A . Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2014; 75(1):111-21. DOI: 10.1007/s00280-014-2617-3. View

10.

Sekiguchi N . [Waldenström macroglobulinemia: Japanese perception]. Rinsho Ketsueki. 2019; 60(8):988-997. DOI: 10.11406/rinketsu.60.988. View

11.

Owen R, Kyle R, Stone M, Rawstron A, Leblond V, Merlini G . Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2012; 160(2):171-6. DOI: 10.1111/bjh.12102. View

12.

Buske C, Tedeschi A, Trotman J, Garcia-Sanz R, MacDonald D, Leblond V . Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2021; 40(1):52-62. PMC: 8683240. DOI: 10.1200/JCO.21.00838. View

13.

Burger J, Barr P, Robak T, Owen C, Ghia P, Tedeschi A . Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2019; 34(3):787-798. PMC: 7214263. DOI: 10.1038/s41375-019-0602-x. View

14.

Kastritis E, Leblond V, Dimopoulos M, Kimby E, Staber P, Kersten M . Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv41-iv50. DOI: 10.1093/annonc/mdy146. View

15.

Buske C, Jurczak W, Salem J, Dimopoulos M . Managing Waldenström's macroglobulinemia with BTK inhibitors. Leukemia. 2022; 37(1):35-46. PMC: 9883164. DOI: 10.1038/s41375-022-01732-9. View

16.

Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning R . A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013; 122(7):1222-32. DOI: 10.1182/blood-2012-12-475111. View